Interpretable radiomics model based on magnetic resonance imaging to predict responses to transarterial chemoembolization for hepatocellular carcinoma

Table 1 Clinical features of the patients

Clinical parameter	Training group (n = 80)				Validation group (n = 36)				P value
	n	Response group (n = 50)	Nonresponse group (n = 30)	P value	n	Response group (n = 22)	Nonresponse group (n = 14)	P value
Sex				0.609				0.956	0.309
Male	73	45	28		31	19	12
Female	7	5	2		5	3	2
Age				0.954				0.204	0.908
≤ 60	45	28	17		21	11	10
> 60	35	22	13		15	11	4
Number of tumors				0.005				0.221	0.502
≤ 1	32	26	6		20	14	6
> 1	48	24	24		16	8	8
Maximum tumor diameter				0.003				0.005	0.212
≤ 8.62	44	34	10		23	18	5
> 8.62	36	16	20		13	4	9
ALBI				0.729				0.878	0.18
1	38	26	12		20	12	8
2	41	23	18		16	10	6
3	1	1	0		0	0
CTP				0.248				0.927	0.257
A	64	42	22		28	17	11
B	16	8	8		8	5	3
Liver cirrhosis				0.383				0.342	0.074
Yes	35	30	15		17	13	6
No	45	20	15		19	9	8
Portal vein tumor thrombus				0.023				0.311	0.629
Yes	14	45	21		14	12	10
No	66	5	9		22	10	4
NLR				0.862				0.4	1
≤ 3.375	39	24	15		16	11	5
< 3.375	41	26	15		20	11	9
PLR				0.602				0.311	0.4
≤ 114.385	37	22	15		22	12	10
> 114.385	43	28	15		14	10	4
ALT (U/L)				0.129				0.592	0.517
≤ 50	46	32	14		25	16	9
> 50	34	18	16		11	6	5
ALB (g/L)				0.729				0.878	1
≤ 40	42	27	15		20	12	8
> 40	38	23	15		16	10	6
AST (U/L)				0.313				0.927	0.571
≤ 40	24	17	7		8	5	3
> 40	56	33	23		28	17	11
AFP (ng/mL)				0.948				0.629	0.93
< 20	28	18	10		9	6	3
20-400	25	15	10		10	7	3
> 400	27	17	10		17	9	8

ALBI: Albumin-bilirubin; CTP: Child-Turcotte-Pugh; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; ALT: Alanine aminotransferase; ALB: Albumin; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein.